BerGenBio ASA (BGBIO.OL)
NOK 1.67
(-2.0%)
NOK 1.67
(-2.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -191.81 Million NOK | 37.24% |
| 2022 | -305.63 Million NOK | 2.81% |
| 2021 | -314.46 Million NOK | -20.44% |
| 2020 | -261.09 Million NOK | -27.75% |
| 2019 | -204.37 Million NOK | -5.06% |
| 2018 | -194.53 Million NOK | -5.9% |
| 2017 | -183.7 Million NOK | -39.63% |
| 2016 | -131.57 Million NOK | -80.42% |
| 2015 | -72.92 Million NOK | -23.97% |
| 2014 | -58.82 Million NOK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -40.87 Million NOK | 6.14% |
| 2024 Q2 | -51.86 Million NOK | -24.2% |
| 2023 Q3 | -28.09 Million NOK | 41.19% |
| 2023 Q2 | -47.76 Million NOK | 34.05% |
| 2023 FY | -191.81 Million NOK | 37.24% |
| 2023 Q1 | -72.42 Million NOK | 5.21% |
| 2023 Q4 | -43.54 Million NOK | -55.02% |
| 2022 Q1 | -78.56 Million NOK | -16.7% |
| 2022 FY | -305.63 Million NOK | 2.81% |
| 2022 Q4 | -76.4 Million NOK | -22.39% |
| 2022 Q3 | -62.42 Million NOK | 29.25% |
| 2022 Q2 | -88.23 Million NOK | -12.31% |
| 2021 Q2 | -92.3 Million NOK | -10.65% |
| 2021 Q3 | -71.41 Million NOK | 22.63% |
| 2021 Q4 | -67.32 Million NOK | 5.74% |
| 2021 Q1 | -83.41 Million NOK | -16.15% |
| 2021 FY | -314.46 Million NOK | -20.44% |
| 2020 Q3 | -68.31 Million NOK | -5.56% |
| 2020 Q4 | -71.82 Million NOK | -5.14% |
| 2020 FY | -261.09 Million NOK | -27.75% |
| 2020 Q1 | -56.23 Million NOK | 4.77% |
| 2020 Q2 | -64.71 Million NOK | -15.08% |
| 2019 Q3 | -47.53 Million NOK | 8.52% |
| 2019 FY | -204.37 Million NOK | -5.06% |
| 2019 Q4 | -59.05 Million NOK | -24.22% |
| 2019 Q2 | -51.96 Million NOK | -13.42% |
| 2019 Q1 | -45.81 Million NOK | 10.0% |
| 2018 Q3 | -38.11 Million NOK | 24.87% |
| 2018 Q4 | -50.9 Million NOK | -33.56% |
| 2018 Q2 | -50.73 Million NOK | 7.39% |
| 2018 FY | -194.53 Million NOK | -5.9% |
| 2018 Q1 | -54.78 Million NOK | -15.3% |
| 2017 Q2 | -33.84 Million NOK | 48.55% |
| 2017 Q1 | -65.78 Million NOK | -134.68% |
| 2017 FY | -183.7 Million NOK | -39.63% |
| 2017 Q3 | -36.56 Million NOK | -8.02% |
| 2017 Q4 | -47.51 Million NOK | -29.95% |
| 2016 FY | -131.57 Million NOK | -80.42% |
| 2016 Q3 | -16.34 Million NOK | 75.41% |
| 2016 Q2 | -66.46 Million NOK | 0.0% |
| 2016 Q4 | -28.03 Million NOK | -71.56% |
| 2015 FY | -72.92 Million NOK | -23.97% |
| 2014 FY | -58.82 Million NOK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Arctic Bioscience AS | -48.58 Million NOK | -294.802% |
| Aqua Bio Technology ASA | -17.85 Million NOK | -974.186% |
| ArcticZymes Technologies ASA | 15.74 Million NOK | 1318.208% |
| Hofseth BioCare ASA | -102.52 Million NOK | -87.088% |
| PCI Biotech Holding ASA | -22.24 Million NOK | -762.457% |
| Thor Medical ASA | -7.16 Million NOK | -2579.036% |
| Ultimovacs ASA | -215.73 Million NOK | 11.086% |